Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy

Bibliography

• Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994;64(3):529-64
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999;10(3):281-7
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Shankaran V, Dighe AS, Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95(13):7556-61
   PubMed Web of Science ®Google Scholar
• Sahin U, Tureci O, Schmitt H, Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92(25):11810-3
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15(17):5323-37
   PubMed Web of Science ®Google Scholar
• Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer 2009;9(9):675-81
   PubMed Web of Science ®Google Scholar
• Inoges S, Rodriguez-Calvillo M, Zabalegui N, Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 2006;98(18):1292-301
   PubMed Web of Science ®Google Scholar
• Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006;6(3):204-16
   PubMed Web of Science ®Google Scholar
• Lage A, Perez R, Fernandez LE. Therapeutic cancer vaccines: at midway between immunology and pharmacology. Curr Cancer Drug Targets 2005;5(8):611-27
   PubMed Web of Science ®Google Scholar
• Saito M, Kitamura H, Sugiyama K. Liver gangliosides of various animals ranging from fish to mammalian species. Comp Biochem Physiol B Biochem Mol Biol 2001;129(4):747-58
   PubMed Web of Science ®Google Scholar
• Saito M, Sugiyama K. Major and c-series gangliosides in lenticular tissues: mammals to molluscs. Comp Biochem Physiol B Biochem Mol Biol 2001;130(3):313-21
   PubMed Web of Science ®Google Scholar
• Suzaki K. The pattern of mammalian brain gangliosides. 3. Regional and developmental differences. J Neurochem 1965;12(12):969-79
   PubMed Web of Science ®Google Scholar
• Wang B, Miller JB, McNeil Y, McVeagh P. Sialic acid concentration of brain gangliosides: variation among eight mammalian species. Comp Biochem Physiol A Mol Integr Physiol 1998;119(1):435-9
   PubMed Web of Science ®Google Scholar
• Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996;56(23):5309-18
   PubMed Web of Science ®Google Scholar
• Livingston PO, Hood C, Krug LM, Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy. Cancer Immunol Immunother 2005;54(10):1018-25
   PubMed Web of Science ®Google Scholar
• Livingston PO, Ragupathi G. Cancer vaccines targeting carbohydrate antigens. Hum Vaccin 2006;2(3):137-43
   PubMed Web of Science ®Google Scholar
• Portoukalian J, Zwingelstein G, Dore JF. Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem 1979;94(1):19-23
   PubMedGoogle Scholar
• Birkle S, Zeng G, Gao L, Role of tumor-associated gangliosides in cancer progression. Biochimie 2003;85(3-4):455-63
   PubMed Web of Science ®Google Scholar
• Deng W, Li R, Ladisch S. Influence of cellular ganglioside depletion on tumor formation. J Natl Cancer Inst 2000;92(11):912-7
   PubMed Web of Science ®Google Scholar
• Alessandri G, Filippeschi S, Sinibaldi P, Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res 1987;47(16):4243-7
   PubMed Web of Science ®Google Scholar
• Ladisch S. Tumor cell gangliosides. Adv Pediatr 1987;34:45-58
   Google Scholar
• Ladisch S, Kitada S, Hays EF. Gangliosides shed by tumor cells enhance tumor formation in mice. J Clin Invest 1987;79(6):1879-82
   PubMed Web of Science ®Google Scholar
• Ladisch S, Wu ZL, Feig S, Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer 1987;39(1):73-6
   PubMed Web of Science ®Google Scholar
• Varki A. Selectins and other mammalian sialic acid-binding lectins. Curr Opin Cell Biol 1992;4(2):257-66
   PubMedGoogle Scholar
• Varki A. Diversity in the sialic acids. Glycobiology 1992;2(1):25-40
   PubMed Web of Science ®Google Scholar
• Muchmore EA, Milewski M, Varki A, Diaz S. Biosynthesis of N-glycolyneuraminic acid. The primary site of hydroxylation of N-acetylneuraminic acid is the cytosolic sugar nucleotide pool. J Biol Chem 1989;264(34):20216-23
   PubMed Web of Science ®Google Scholar
• Varki A. Loss of N-glycolylneuraminic acid in humans: mechanisms, consequences, and implications for hominid evolution. Am J Phys Anthropol 2001;(Suppl 33):54-69
   PubMedGoogle Scholar
• Varki A. N-glycolylneuraminic acid deficiency in humans. Biochimie 2001;83(7):615-22
   PubMed Web of Science ®Google Scholar
• Malykh YN, Schauer R, Shaw L. N-Glycolylneuraminic acid in human tumours. Biochimie 2001;83(7):623-34
   PubMed Web of Science ®Google Scholar
• Marquina G, Waki H, Fernandez LE, Gangliosides expressed in human breast cancer. Cancer Res 1996;56(22):5165-71
   PubMed Web of Science ®Google Scholar
• Oliva JP, Valdes Z, Casaco A, Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with 99mTc. Breast Cancer Res Treat 2006;96(2):115-21
   PubMed Web of Science ®Google Scholar
• Carr A, Mullet A, Mazorra Z, A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000;19(3):241-7
   PubMed Web of Science ®Google Scholar
• de Leon J, Fernandez A, Mesa C, Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother 2006;55(4):443-50
   PubMed Web of Science ®Google Scholar
• de Leon J, Fernandez A, Clavell M, Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25– effector and naturally occurring CD4+CD25+ regulatory T cells function. Int Immunol 2008;20(4):591-600
   PubMed Web of Science ®Google Scholar
• Carr A, Rodriguez E, Arango Mdel C, Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol 2003;21(6):1015-21
   PubMed Web of Science ®Google Scholar
• Estevez F, Carr A, Solorzano L, Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 1999;18(1-2):190-7
   PubMed Web of Science ®Google Scholar
• Eisenbach L, Hollander N, Greenfeld L, The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int J Cancer 1984;34(4):567-73
   PubMed Web of Science ®Google Scholar
• Muthing J, Steuer H, Peter-Katalinic J, Expression of gangliosides GM3 (NeuAc) and GM3 (NeuGc) in myelomas and hybridomas of mouse, rat, and human origin. J Biochem 1994;116(1):64-73
   PubMed Web of Science ®Google Scholar
• Duclos RI Jr. The total synthesis of ganglioside GM3. Carbohydr Res 2000;328(4):489-507
   PubMed Web of Science ®Google Scholar
• Sherman AA, Yudina ON, Shashkov AS, Preparative route to N-glycolylneuraminic acid phenyl 2-thioglycoside donor and synthesis of Neu5Gc-alpha-(2→3′)-lactosamine 3-aminopropyl glycoside. Carbohydr Res 2002;337(5):451-7
   PubMed Web of Science ®Google Scholar
• Saito M, Kasai N, Yu RK. In situ immunological determination of basic carbohydrate structures of gangliosides on thin-layer plates. Anal Biochem 1985;148(1):54-8
   PubMed Web of Science ®Google Scholar
• Alonso DF, Gabri MR, Guthmann MD, A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma. Int J Oncol 1999;15(1):59-66
   PubMed Web of Science ®Google Scholar
• Coulombe J, Pelletier G. Gangliosides and organ-specific metastatic colonization. Int J Cancer 1993;53(1):104-9
   PubMed Web of Science ®Google Scholar
• Makatsori E, Fermani K, Aletras A, Screening of N-acylneuraminic acids in serum and tissue specimens of mouse C57BI with Lewis' lung cancer by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998;712(1-2):23-9
   PubMedGoogle Scholar
• El-Abbadi M, Seyfried TN, Yates AJ, Ganglioside composition and histology of a spontaneous metastatic brain tumour in the VM mouse. Br J Cancer 2001;85(2):285-92
   PubMed Web of Science ®Google Scholar
• Dickler MN, Ragupathi G, Liu NX, Immunogenicity of a fucosyl–GM1–keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res 1999;5(10):2773-9
   PubMed Web of Science ®Google Scholar
• Dumontet C, Rebbaa A, Portoukalian J. Very low density lipoproteins and interleukin 2 enhance the immunogenicity of 9-O-acetyl-GD3 ganglioside in BALB/c mice. J Immunol Methods 1997;206(1-2):115-23
   PubMed Web of Science ®Google Scholar
• Livingston PO, Calves MJ, Helling F, GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3. Vaccine 1993;11(12):1199-204
   PubMed Web of Science ®Google Scholar
• Livingston PO, Calves MJ, Natoli EJ Jr. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells. J Immunol 1987;138(5):1524-9
   PubMed Web of Science ®Google Scholar
• Livingston PO, Ritter G, Calves MJ. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse. Cancer Immunol Immunother 1989;29(3):179-84
   PubMed Web of Science ®Google Scholar
• Livingston PO, Ritter G, Srivastava P, Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989;49(24 Pt 1):7045-50
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang S, Cheung NK, Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res 1998;58(13):2844-9
   PubMed Web of Science ®Google Scholar
• Helling F, Zhang S, Shang A, GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995;55(13):2783-8
   PubMed Web of Science ®Google Scholar
• Kim SK, Ragupathi G, Cappello S, Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1–KLH and GD3–KLH conjugates. Vaccine 2000;19(4-5):530-7
   PubMed Web of Science ®Google Scholar
• Livingston PO. Experimental and clinical studies with active specific immunotherapy. Prog Clin Biol Res 1989;288:309-21
   PubMedGoogle Scholar
• Livingston PO. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 1995;145:147-66
   PubMed Web of Science ®Google Scholar
• Livingston PO, Ragupathi G. Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother 1997;45(1):10-9
   PubMed Web of Science ®Google Scholar
• Livingston PO. Augmenting the immunogenicity of carbohydrate tumor antigens. Semin Cancer Biol 1995;6(6):357-66
   PubMed Web of Science ®Google Scholar
• Ravindranath MH, Kelley MC, Jones RC, Ratio of IgG:IgM antibodies to sialyl LewisX and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice. Int J Cancer 1998;75(1):117-24
   PubMed Web of Science ®Google Scholar
• Ambrosino DM, Bolon D, Collard H, Effect of Haemophilus influenzae polysaccharide outer membrane protein complex conjugate vaccine on macrophages. J Immunol 1992;149(12):3978-83
   PubMed Web of Science ®Google Scholar